LifeMD (NASDAQ:LFMD) Given New $14.00 Price Target at BTIG Research

LifeMD (NASDAQ:LFMD) had its target price boosted by BTIG Research from $13.00 to $14.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright upped their price objective on LifeMD from $10.00 to $12.00 and gave the company a buy rating in a research report on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $10.40.

LifeMD Trading Up 8.9 %

Shares of LFMD opened at $10.89 on Tuesday. The stock has a market capitalization of $439.63 million, a PE ratio of -15.56 and a beta of 1.43. The company’s fifty day moving average is $9.16 and its 200 day moving average is $7.67. The company has a debt-to-equity ratio of 3.22, a quick ratio of 1.15 and a current ratio of 1.22. LifeMD has a fifty-two week low of $1.40 and a fifty-two week high of $12.01.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Monday, March 11th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $44.86 million during the quarter, compared to the consensus estimate of $40.65 million. Sell-side analysts expect that LifeMD will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LifeMD

A number of large investors have recently made changes to their positions in the company. G2 Investment Partners Management LLC raised its position in LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after purchasing an additional 132,850 shares during the period. Jump Financial LLC grew its stake in shares of LifeMD by 50.2% during the fourth quarter. Jump Financial LLC now owns 111,738 shares of the company’s stock valued at $926,000 after buying an additional 37,339 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of LifeMD in the fourth quarter worth approximately $815,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of LifeMD during the 3rd quarter worth approximately $577,000. Finally, Cantor Fitzgerald L. P. purchased a new position in LifeMD during the 4th quarter valued at $653,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.